Brief: Celldex Therapeutics Presents Positive Data From Barzolvolimab Chronic Urticaria Program At Eaaci 2023
10/06/2023 15:47
June 10 (Reuters) - Celldex Therapeutics Inc CLDX.O :
* CELLDEX THERAPEUTICS PRESENTS POSITIVE DATA FROM
BARZOLVOLIMAB
CHRONIC URTICARIA PROGRAM AT EAACI 2023
* CELLDEX THERAPEUTICS - PHASE 2 CSU STUDY NEARING
ENROLLMENT
COMPLETION WITH TOPLINE DATA BY YEAR-END; PHASE 2 CINDU STUDY
ENROLLING AS PLANNED
Source text for Eikon: ID:nGNX3SZ6jt
Further company coverage: CLDX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials